Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : ZL-6201
Therapeutic Area : Oncology
Study Phase : Preclinical
Recipient : Zai Lab
Deal Size : Undisclosed
Deal Type : Collaboration
Zai Lab Forms Partnership with MediLink for LRRC15 ADC Development
Details : Through the collaboration, Zai Lab further expands its oncology pipeline with another potential first-in-class, ADC ZL-6201 targeting multiple solid tumors.
Product Name : ZL-6201
Product Type : Antibody-drug Conjugate
Upfront Cash : Undisclosed
January 09, 2025
Lead Product(s) : ZL-6201
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Recipient : Zai Lab
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : YL201,Tarlatamab
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Amgen Inc
Deal Size : Undisclosed
Deal Type : Collaboration
MediLink And YL201 Collaborate on Global Clinical Trial And Supply Agreement
Details : Amgen will lead a global clinical study to evaluate the potential of the combination of MediLink's B7-H3-targeting ADC YL201 and Amgen's DLL3- and CD3-targeting BiTE® IMDELLTRA™ in ES-SCLC.
Product Name : YL201
Product Type : Large molecule
Upfront Cash : Undisclosed
October 07, 2024
Lead Product(s) : YL201,Tarlatamab
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Amgen Inc
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : YL211
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : F. Hoffmann-La Roche
Deal Size : $1,000.0 million
Deal Type : Collaboration
MediLink Announces Collaboration with Roche for Antibody Drug Conjugate
Details : Under the agreement, MediLink will grant Roche exclusive global rights for the development, manufacturing, and commercialization of YL211, an antibody-drug conjugate for solid tumors.
Product Name : YL211
Product Type : Large molecule
Upfront Cash : $50.0 million
January 02, 2024
Lead Product(s) : YL211
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : F. Hoffmann-La Roche
Deal Size : $1,000.0 million
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : BioNTech
Deal Size : $1,070.0 million
Deal Type : Licensing Agreement
Details : Under the terms of the agreement, MediLink will grant BioNTech exclusive global rights for the development, manufacturing, and commercialization of one of MediLink's ADC assets, against Human Epidermal Growth Factor Receptor 3 (HER3).
Product Name : Undisclosed
Product Type : Large molecule
Upfront Cash : $70.0 million
October 12, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : BioNTech
Deal Size : $1,070.0 million
Deal Type : Licensing Agreement